Ranadheera, S., & Ajlouni, S
The Food and Drug Administration (FDA) approved the use of GLP-1 analogs for some people as a weight loss treatment for obesity
Chung YW, Lee JH, Lee JY, et al
What We Know About GLP-1s and Bone Density New research presents a complex picture regarding the impact of GLP-1 medications on bone health
While GLP-1 medications are not a 'quick fix,' they can be a powerful tool for regaining momentum, reducing health risks, and supporting long-term weight management goals
In the LIVE trial, liraglutide treatment resulted in no change in left ventricular systolic function, whereas liraglutide related to an increase in heart rate and more serious cardiac adverse events among chronic heart failure patients with and without type 2 diabetes [45]